Testing AP402 for her2-positive advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a HER2-positive solid tumor that is advanced or has spread, and standard treatments are no longer working.
- You are 18 years or older.
- You have at least one tumor that can be measured on a scan and is at least 1 cm in size.
- Your cancer has not gotten better after prior treatments and you have not had certain other cancer treatments within the last 28 days.
- You do not have untreated or unstable brain metastases.
- You have adequate organ function (like kidney, liver, and blood counts) as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This trial tests a new drug called AP601 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and it targets CD73 and CD137 pathways to help your immune system fight cancer.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.